Lecanemab 注射剂市场：2025-2030 年全球预测（按患者分期、患者年龄、最终用户和分销管道）

预计 2024 年 Lecanemab 注射剂市场规模将达到 5.1305 亿美元，2025 年成长至 5.4173 亿美元，到 2030 年将达到 7.1563 亿美元，复合年增长率为 5.70%。

主要市场统计数据
基准年2024年	5.1305亿美元
预计2025年	5.4173亿美元
预测年份 2030	7.1563亿美元
复合年增长率（%）	5.70%

揭示乐卡尼单抗注射液在阿兹海默症治疗中的重要角色及其对全球医疗网路治疗范式的影响

阿兹海默症仍然是神经病学领域最艰鉅的挑战之一，推动着缓解疾病疗法的持续创新。 Lecanemab 是一种可注射的抗淀粉样β蛋白原纤维抗体，它透过针对认知衰退早期的淀粉样蛋白聚集，代表着模式转移。其选择性结合原纤维的机制，为寻求超越症状治疗的干预措施的临床医生和患者带来了新的希望。

探索Lecanemab创新和以患者为中心的全新护理策略为阿兹海默症治疗带来的变革

随着注射用lecanemab从临床试验走向临床实践，阿兹海默症的治疗模式正在发生重大转变。淀粉样蛋白清除和认知稳定性的疗效数据促使人们重新审视治疗目标和患者选择标准。因此，目前的治疗流程优先考虑生物标记主导的通路，使轻度认知障碍患者能够接受快速评估和潜在的抗体治疗。

评估2025年美国关税对阿兹海默症生技药品供应链的累积影响：监管格局与成本结构

美国关税将于2025年生效，预计将影响包括抗淀粉样蛋白抗体在内的生物製药的供应动态。对原料药和成品药的进口关税上调可能会增加依赖全球生产网络的製药公司的生产成本。为此，製药公司正在评估本地生产能力和替代筹资策略，以减轻关税的影响。

从患者阶段、最终用户和分销管道细分中获得客製化见解，以揭示老年痴呆症的失智症采用模式

对于阿兹海默症的治疗，对患者群体进行细分可以揭示重要的见解，从而指导有针对性的干预措施。以疾病分期评估，早期阿兹海默症患者对抗体治疗的反应通常优于中度认知衰退患者，这凸显了及时诊断和开始治疗的重要性。同样，轻度认知功能障碍患者是关键族群，预防策略可能带来显着的长期益处。

检验美洲、欧洲、中东和非洲以及亚太市场阿兹海默症治疗发展的不同区域动态

阿兹海默症治疗应用的区域动态揭示了由医疗基础设施、报销政策和人口统计特征塑造的微妙趋势。在美洲，支付方和医疗服务提供者正在率先采用基于疗效的报销模式，并透过专门的记忆护理网络扩大医疗覆盖范围。早期采用此疗法的地区正在神经科科诊所旁开设输液中心，以满足日益增长的抗体治疗需求。

重点介绍推动阿兹海默症研究进步和先进治疗解决方案竞争差异化的关键生物製药创新者

领先的生物製药公司透过强大的研发管线、策略联盟和有针对性的商业化努力，推动了阿兹海默症的研究。在Lecanemab的开发中，双方的开创性合作开创了共用神经退化生物学和临床业务专业知识的共同开发模式。同时，竞争对手也在寻求其他靶点，例如Tau聚集和神经发炎路径。

医疗保健相关人员优化 Lecanemab 整合的策略行动计划，旨在改善患者疗效并巩固市场地位

医疗保健相关人员应积极调整治疗途径，以优化Lecanemab在多学科照护框架内的整合。建立专业的输液单元并培养专业的护理团队可以增强病人安全并简化行政工作流程。此外，儘早与付款方沟通，协商基于价值的合同，可以降低报销的不确定性，并展现对患者疗效的承诺。

利用一手和二手研究及分析方法的综合研究框架，确保对阿兹海默症治疗评估具有可靠的洞察力

我们的调查方法融合了严谨的原始研究和二手资料收集，以确保基于实证证据和行业最佳实践的洞察。原始研究包括对神经科、输液中心主任、付款方代表和监管专家的深入访谈，提供有关治疗方法采用和运营挑战的第一手观点。

老年痴呆症失智症治疗的关键发现和未来考虑总结：确定 lecanemab 和新治疗方式的前进道路

本执行摘要综合了临床、监管和营运领域的证据，重点介绍了Lecanemab注射液如何重新定义阿兹海默症的治疗途径。早期疗育策略、自适应授权模式以及以患者为中心的数位化解决方案，标誌着我们正朝着更个人化和积极主动的治疗模式转变。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 扩大主要市场的报销途径将促进 lecanemab 的商业化上市
• 血浆生物标记的整合加速了 lecanemab 治疗患者的识别
• 真实世界数据揭示了安全性和有效性趋势，这将影响临床医生对 lecanemab 的采用
• 联合生产倡议解决了全球 lecanemab 推广中的供应限制
• 生物相似药产品线瞄准 Lecanemab专利到期，竞争格局加剧
• 付款人谈判策略不断发展，以解决阿兹海默症症 Lecanemab 疗法的高成本问题
• 亚太地区新法规结构有利于有条件核准lecanemab 用于治疗阿兹海默症
• 融入临床实践的数位监测工具可提高阿兹海默症患者对 lecanemab 治疗的长期依从性
• 病患权益团体正在影响政策变化，以改善医疗服务不足地区获得 lecanemab 的机会。
• 卫生技术评估结合真实世界证据，重新定义Lecanemab在阿兹海默症治疗中的价值提案

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

8. Lecanemab 注射液市场（依病患阶段）

• 早期阿兹海默症
• 轻度认知障碍
• 中度阿兹海默症

9. Lecanemab 注射剂市场（依患者年龄）

• 60-70岁
• 71至80岁
• 81岁或以上

第 10 章 Lecanemab 注射剂市场（按最终用户划分）

• 家庭医疗保健
• 医院
• 长期照护机构
• 专科诊所

第 11 章 Lecanemab 注射液市场（依通路）

• 医院药房
• 网路药局
• 零售药局

12.美洲Lecanemab注射液市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

13. 欧洲、中东和非洲Lecanemab注射液市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

14. 亚太地区Lecanemab注射液市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十五章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Eisai Co., Ltd.
  • BioArctic AB
  • Biogen Inc.
  • Soleo Health

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

The Lecanemab Injection Market was valued at USD 513.05 million in 2024 and is projected to grow to USD 541.73 million in 2025, with a CAGR of 5.70%, reaching USD 715.63 million by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 513.05 million
Estimated Year [2025]	USD 541.73 million
Forecast Year [2030]	USD 715.63 million
CAGR (%)	5.70%

Unveiling the Critical Role of Lecanemab Injection in Alzheimer's Care and Its Implications for Treatment Paradigms Across Global Healthcare Networks

Alzheimer's disease continues to pose one of the most formidable challenges in neurology, driving relentless innovation toward disease-modifying treatments. Lecanemab injection, an anti-amyloid beta protofibril antibody, represents a paradigm shift by targeting amyloid aggregation in early stages of cognitive decline. Its mechanism of selectively binding protofibrils has brought renewed hope to clinicians and patients seeking interventions beyond symptomatic relief.

Since receiving regulatory clearance for early Alzheimer's disease, Lecanemab has sparked discourse around treatment timing, biomarker screening, and infusion protocols. Clinicians emphasize the importance of early intervention, given that neurodegeneration advances long before clinical symptoms emerge. Consequently, diagnosis frameworks are adapting to integrate advanced PET imaging and fluid biomarkers, ensuring eligible patients may benefit from antibody therapy at optimal stages.

Moreover, healthcare systems are exploring infusion centers, specialized memory clinics, and coordinated care pathways to manage administration and monitoring. These developments illustrate a shift from primary care-led management toward multidisciplinary teams that encompass neurologists, radiologists, and dementia specialists. As a result, the introduction of Lecanemab has catalyzed structural changes in care delivery models, emphasizing early detection and personalized treatment plans.

Exploring Transformative Shifts in Alzheimer's Therapeutics Landscape Driven by Lecanemab Innovations and Emerging Patient-Centric Care Strategies

The Alzheimer's treatment landscape has undergone transformative shifts as Lecanemab injection moves from clinical trials into real-world practice. Its efficacy data, demonstrating amyloid clearance and cognitive stabilization, has stimulated a reexamination of therapeutic goals and patient selection criteria. Consequently, treatment algorithms now prioritize biomarker-driven pathways, ensuring individuals with mild cognitive impairment receive prompt evaluation and potential antibody therapy.

Furthermore, regulatory agencies have introduced accelerated approval frameworks and managed-access programs to expedite availability. These initiatives underscore a broader trend toward adaptive licensing, wherein post-approval studies inform label modifications and access expansions. At the same time, payers are evaluating innovative reimbursement models that tie payment to clinical outcomes, reflecting a shift toward value-based care.

Meanwhile, patient advocacy groups and social support organizations have intensified outreach to educate communities about early warning signs and diagnostic resources. This patient-centric movement has fostered digital health solutions including remote cognitive assessments and telemedicine consultations. As these complementary innovations gain traction, they are poised to further reshape how antibodies like Lecanemab integrate into holistic Alzheimer's care.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Alzheimer's Biologics Supply Chains Regulatory Landscape and Cost Structures

United States tariffs set to take effect in 2025 are expected to influence the supply dynamics of biologic therapies including anti-amyloid antibodies. Increased import duties on active pharmaceutical ingredients and finished formulations may elevate manufacturing costs for providers reliant on global production networks. In response, pharmaceutical companies are evaluating localized manufacturing capabilities and alternative sourcing strategies to mitigate tariff impacts.

Moreover, infusion centers and hospital pharmacies are assessing potential cost adjustments and inventory management plans. Some stakeholders plan to negotiate long-term contracts that lock in favorable pricing before tariffs are implemented. Others are exploring strategic stockpiling of key reagents and leveraging contract manufacturing organizations located in tariff-exempt jurisdictions.

At the same time, regulatory compliance teams are working to align procurement practices with evolving trade regulations, ensuring uninterrupted access to necessary infusion supplies and cold chain logistics. As a result, collaborative efforts between supply chain specialists, legal advisors, and clinical operations units have intensified. These measures aim to preserve treatment continuity for patients while maintaining financial sustainability across the distribution network.

Uncovering Tailored Insights from Patient Stage Age End User and Distribution Channel Segmentation to Illuminate Alzheimer's Treatment Adoption Patterns

In Alzheimer's therapeutics, segmenting the patient population reveals critical insights that guide targeted interventions. When evaluated by disease stage, individuals diagnosed with early Alzheimer's disease often demonstrate greater responsiveness to antibody therapy compared to those with moderate cognitive decline, highlighting the importance of prompt diagnosis and initiation of treatment. Similarly, those presenting mild cognitive impairment occupy a pivotal position where preventative strategies may yield substantial long-term benefits.

Age-based segmentation further refines treatment considerations. Patients within the 60-70-year cohort tend to exhibit fewer comorbidities and better tolerability profiles, whereas those aged 71-80 require more rigorous safety monitoring. In the oldest group, 81 years and above, treatment decisions frequently hinge on holistic assessments that account for frailty and quality-of-life priorities.

End-user environments shape care delivery and resource allocation. Home healthcare services must adapt infusion protocols for ambulatory settings, while hospital and specialty clinics focus on centralized infusion suites and neurologist-led monitoring. Long term care facilities, conversely, emphasize interdisciplinary collaboration to integrate antibody therapy into established dementia care regimens.

Distribution channel analysis underscores the evolving role of hospital pharmacies as primary infusion suppliers, with online pharmacies emerging for at-home administration support and retail pharmacies serving adjunctive medication needs. These varied channels collectively enhance accessibility and streamline therapy initiation across diverse care environments.

Examining the Diverse Regional Dynamics of Alzheimer's Treatment Developments across Americas Europe Middle East Africa and Asia-Pacific Markets

Regional dynamics in Alzheimer's therapy adoption reveal nuanced trends shaped by healthcare infrastructure, reimbursement policies, and demographic profiles. In the Americas, payers and providers are pioneering outcome-based reimbursement models and expanding access through dedicated memory care networks. Early adopter regions have established infusion centers alongside neurology clinics to accommodate growing demand for antibody treatments.

Meanwhile, Europe, the Middle East, and Africa exhibit heterogeneous trajectories. Western European nations with centralized health systems have integrated amyloid imaging and infusion services into national dementia strategies, whereas emerging markets in the region are building capacity through public-private partnerships and targeted training programs for neurologists. Reimbursement negotiations often hinge on real-world evidence, with health technology assessment bodies requiring post-launch data to inform coverage decisions.

In Asia-Pacific, governments and industry leaders are collaborating to accelerate clinical trial participation and expand biomarker screening. Countries with aging populations are investing in diagnostic infrastructure, while regional hubs are emerging as manufacturing centers for monoclonal antibody formulations. Throughout the region, cross-border alliances and knowledge-sharing forums are fostering rapid dissemination of best practices in infusion management and patient monitoring.

Highlighting Leading Biopharmaceutical Innovators Driving Alzheimer's Research Progress and Competitive Differentiation in Advanced Therapeutic Solutions

Leading biopharmaceutical organizations have advanced Alzheimer's research through robust pipelines, strategic alliances, and targeted commercialization efforts. The pioneering collaboration behind the development of Lecanemab has set a precedent for co-development models that leverage shared expertise in neurodegenerative biology and clinical operations. At the same time, competitors are pursuing alternative targets such as tau protein aggregation and neuroinflammation pathways.

Several established players have diversified their portfolios with complementary therapies, including small molecule candidates and combination regimens designed to address downstream neurodegenerative cascades. New entrants are leveraging artificial intelligence to accelerate target discovery and optimize antibody engineering. Meanwhile, contract research organizations support adaptive clinical trial designs that facilitate rapid dose optimization and endpoint validation.

Together, these companies are shaping a competitive landscape characterized by both differentiation and convergence. Differentiation arises from proprietary biomarker strategies and novel delivery mechanisms, whereas convergence is seen in cross-licensing agreements and joint ventures aimed at expanding global manufacturing capacity. As a result, stakeholders across the value chain continue to prioritize collaborative innovation to expedite therapeutic breakthroughs.

Strategic Action Plans for Healthcare Stakeholders to Optimize Lecanemab Integration Enhance Patient Outcomes and Strengthen Market Positioning

Healthcare stakeholders should proactively align care pathways to optimize Lecanemab integration within multidisciplinary treatment frameworks. Establishing specialized infusion units and training dedicated nursing teams can enhance patient safety and streamline administration workflows. In addition, early engagement with payers to negotiate value-based agreements will mitigate reimbursement uncertainty and demonstrate commitment to patient outcomes.

Moreover, providers and life sciences organizations should invest in digital platforms that facilitate remote cognitive monitoring and patient education. Leveraging telehealth capabilities can expand access for individuals in underserved regions and improve adherence through real-time support. Simultaneously, forging alliances with geriatric and primary care networks will bolster referral pathways and accelerate diagnosis rates.

Furthermore, manufacturing partners and logistics providers must implement robust supply chain visibility tools to anticipate tariff-related disruptions. Scenario planning exercises and strategic procurement agreements will safeguard inventory levels and control cost volatility. Collectively, these strategic actions will strengthen market positioning, foster sustainable growth, and ultimately enhance the standard of care for individuals affected by Alzheimer's disease.

Comprehensive Research Framework Leveraging Primary Secondary Data and Analytical Approaches to Ensure Robust Insights for Alzheimer's Therapeutic Evaluation

Our research methodology integrates rigorous primary and secondary data collection to ensure insights are grounded in empirical evidence and industry best practices. Primary research includes detailed interviews with neurologists, infusion center directors, payer representatives, and regulatory experts who provide first-hand perspectives on therapeutic adoption and operational challenges.

Secondary research draws upon peer-reviewed journals, clinical trial registries, regulatory documents, and publicly available financial disclosures. We employ a systematic literature review process, followed by data triangulation techniques to validate findings across multiple sources. This approach minimizes bias and enhances the reliability of market dynamics interpretation.

Analytical frameworks such as SWOT and Porter's Five Forces are adapted to evaluate competitive positioning and emerging opportunities. In addition, geographic information system analyses support regional insights by mapping infrastructure density and demographic trends. Finally, our quality assurance protocols include cross-validation with external experts and iterative feedback loops, resulting in a comprehensive and dependable assessment of the Alzheimer's therapeutic landscape.

Summarizing Key Learnings and Future Considerations in Alzheimer's Therapeutics Illuminating the Path Forward for Lecanemab and Emerging Treatment Modalities

By consolidating evidence across clinical, regulatory, and operational domains, this executive summary highlights how Lecanemab injection is redefining Alzheimer's care pathways. Early intervention strategies, adaptive licensing models, and patient-centric digital solutions collectively demonstrate a shift toward more personalized and proactive treatment paradigms.

Looking ahead, the integration of real-world data and biomarker validation studies will further refine patient selection criteria and optimize therapeutic outcomes. Moreover, continued collaboration between industry, academia, and healthcare systems promises to accelerate the development of complementary therapies that target diverse aspects of Alzheimer's pathology.

Ultimately, sustained progress will depend on orchestrated efforts across the value chain-from clinical trial innovation and payer partnerships to supply chain resilience and provider education. These converging initiatives set the stage for transformative improvements in patient quality of life and healthcare efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Lecanemab commercial launch driven by expanded reimbursement pathways across major markets
• 5.2. Integration of plasma biomarkers accelerates patient identification for lecanemab treatment
• 5.3. Real-world data reveals safety and efficacy trends shaping lecanemab adoption among clinicians
• 5.4. Collaborative manufacturing initiatives address supply constraints for global lecanemab rollout
• 5.5. Competitive landscape intensifies as biosimilar pipelines target lecanemab patent expiration window
• 5.6. Payer negotiation strategies evolve to accommodate high-cost lecanemab therapy in Alzheimer's care
• 5.7. Emerging regulatory frameworks in Asia-Pacific expedite conditional approvals for lecanemab in Alzheimer's treatment landscapes
• 5.8. Digital monitoring tools integrated into clinical practice boost long-term adherence rates for lecanemab therapy in Alzheimer's patients
• 5.9. Patient advocacy groups influence policy changes to improve lecanemab access across underserved communities
• 5.10. Health technology assessments incorporate real-world evidence to redefine lecanemab value proposition in Alzheimer's care

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Lecanemab Injection Market, by Patient Stage

• 8.1. Introduction
• 8.2. Early Alzheimer's Disease
• 8.3. Mild Cognitive Impairment
• 8.4. Moderate Alzheimer's Disease

9. Lecanemab Injection Market, by Patient Age

• 9.1. Introduction
• 9.2. 60-70 years
• 9.3. 71-80 years
• 9.4. 81+ years

10. Lecanemab Injection Market, by End User

• 10.1. Introduction
• 10.2. Home Healthcare
• 10.3. Hospitals
• 10.4. Long Term Care Facilities
• 10.5. Specialty Clinics

11. Lecanemab Injection Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Americas Lecanemab Injection Market

• 12.1. Introduction
• 12.2. United States
• 12.3. Canada
• 12.4. Mexico
• 12.5. Brazil
• 12.6. Argentina

13. Europe, Middle East & Africa Lecanemab Injection Market

• 13.1. Introduction
• 13.2. United Kingdom
• 13.3. Germany
• 13.4. France
• 13.5. Russia
• 13.6. Italy
• 13.7. Spain
• 13.8. United Arab Emirates
• 13.9. Saudi Arabia
• 13.10. South Africa
• 13.11. Denmark
• 13.12. Netherlands
• 13.13. Qatar
• 13.14. Finland
• 13.15. Sweden
• 13.16. Nigeria
• 13.17. Egypt
• 13.18. Turkey
• 13.19. Israel
• 13.20. Norway
• 13.21. Poland
• 13.22. Switzerland

14. Asia-Pacific Lecanemab Injection Market

• 14.1. Introduction
• 14.2. China
• 14.3. India
• 14.4. Japan
• 14.5. Australia
• 14.6. South Korea
• 14.7. Indonesia
• 14.8. Thailand
• 14.9. Philippines
• 14.10. Malaysia
• 14.11. Singapore
• 14.12. Vietnam
• 14.13. Taiwan

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Eisai Co., Ltd.
  • 15.3.2. BioArctic AB
  • 15.3.3. Biogen Inc.
  • 15.3.4. Soleo Health

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

• FIGURE 1. LECANEMAB INJECTION MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 14. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 16. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. LECANEMAB INJECTION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 22. LECANEMAB INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 23. LECANEMAB INJECTION MARKET: RESEARCHAI
• FIGURE 24. LECANEMAB INJECTION MARKET: RESEARCHSTATISTICS
• FIGURE 25. LECANEMAB INJECTION MARKET: RESEARCHCONTACTS
• FIGURE 26. LECANEMAB INJECTION MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. LECANEMAB INJECTION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LECANEMAB INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY EARLY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY EARLY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MILD COGNITIVE IMPAIRMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY MODERATE ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 60-70 YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 60-70 YEARS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 71-80 YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 71-80 YEARS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 81+ YEARS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY 81+ YEARS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LECANEMAB INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 44. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 45. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 46. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 47. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 48. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 49. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 50. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 51. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. AMERICAS LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 53. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 54. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 55. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 56. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 57. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 58. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 59. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 60. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 61. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 62. UNITED STATES LECANEMAB INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 63. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 64. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 65. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 66. CANADA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 67. CANADA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 68. CANADA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 69. CANADA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 70. CANADA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 71. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 72. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 73. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 74. MEXICO LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 75. MEXICO LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 76. MEXICO LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 77. MEXICO LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 78. MEXICO LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 79. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 80. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 81. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 82. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 83. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 84. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 85. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 86. BRAZIL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 87. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 88. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 89. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 90. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 91. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 92. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 93. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 94. ARGENTINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 95. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 96. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 97. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 105. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 106. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 107. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 108. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 109. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 110. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 111. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 112. UNITED KINGDOM LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 113. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 114. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 115. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 116. GERMANY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 117. GERMANY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 118. GERMANY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 119. GERMANY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 120. GERMANY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 121. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 122. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 123. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 124. FRANCE LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 125. FRANCE LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 126. FRANCE LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 127. FRANCE LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 128. FRANCE LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 129. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 130. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 131. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 132. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 133. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 134. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 135. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 136. RUSSIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 137. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 138. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 139. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 140. ITALY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 141. ITALY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 142. ITALY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 143. ITALY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 144. ITALY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 145. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 146. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 147. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 148. SPAIN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 149. SPAIN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 150. SPAIN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 151. SPAIN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 152. SPAIN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 153. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 154. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 155. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 156. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 157. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 158. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 159. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 160. UNITED ARAB EMIRATES LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 162. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 164. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 167. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 168. SAUDI ARABIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 170. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 171. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 172. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 173. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 174. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 175. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 176. SOUTH AFRICA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 177. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 178. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 179. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 180. DENMARK LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 181. DENMARK LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 182. DENMARK LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 183. DENMARK LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 184. DENMARK LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 185. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 186. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 187. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 188. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 189. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 191. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 192. NETHERLANDS LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 193. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 194. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 195. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 196. QATAR LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 197. QATAR LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 198. QATAR LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 199. QATAR LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 200. QATAR LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 201. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 202. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 203. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 204. FINLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 205. FINLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 206. FINLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 207. FINLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 208. FINLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 209. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 210. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 211. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 212. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 213. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 215. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 216. SWEDEN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 217. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 218. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 219. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 220. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 221. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 222. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 223. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 224. NIGERIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 225. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 226. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 227. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 228. EGYPT LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 229. EGYPT LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. EGYPT LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 231. EGYPT LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 232. EGYPT LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 233. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 234. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 235. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 236. TURKEY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 237. TURKEY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. TURKEY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 239. TURKEY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 240. TURKEY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 241. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 242. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 243. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 244. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 245. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 247. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. ISRAEL LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 249. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 250. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 251. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 252. NORWAY LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 253. NORWAY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 254. NORWAY LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 255. NORWAY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 256. NORWAY LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 257. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 258. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 259. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 260. POLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 261. POLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. POLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 263. POLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. POLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 265. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 266. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 267. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 268. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 269. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 271. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. SWITZERLAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 273. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 274. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 275. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 276. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 277. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 279. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 280. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 281. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC LECANEMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 283. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 284. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 285. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 286. CHINA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 287. CHINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. CHINA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 289. CHINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. CHINA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 291. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 292. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 293. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 294. INDIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 295. INDIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 296. INDIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 297. INDIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 298. INDIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 299. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 300. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 301. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 302. JAPAN LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 303. JAPAN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. JAPAN LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 305. JAPAN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. JAPAN LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 307. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 308. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 309. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 310. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 311. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 312. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 313. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 314. AUSTRALIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 315. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 316. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 317. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 318. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 319. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 320. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 321. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 322. SOUTH KOREA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 323. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 324. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 325. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 326. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 327. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 328. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 329. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 330. INDONESIA LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 331. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 332. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 333. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 334. THAILAND LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
• TABLE 335. THAILAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 336. THAILAND LECANEMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 337. THAILAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 338. THAILAND LECANEMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 339. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2018-2024 (USD MILLION)
• TABLE 340. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT STAGE, 2025-2030 (USD MILLION)
• TABLE 341. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
• TABLE 342. PHILIPPINES LECANEMAB INJECTION MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)

TA